Yes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.72 which represents a decrease of $-0.74 or -2.69% from the prior close of $27.46. The stock opened at $27.11 and touched a low ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Shares in AbbVie slumped by double digits Monday after the company disclosed its psychiatric medicine emraclidine didn’t best ...

Yet, despite recently beating analysts' expectations for the third quarter on both the top and bottom lines -- while also raising full-year guidance -- Zoetis' share price has slid 12% in the last ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...

India should focus on enhancing local vaccine manufacturing and research for better control over safety, according to GTRI. They also suggest investigating adverse health events post-vaccination to ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...